OMERS ADMINISTRATION Corp Takes Position in Pro-Dex, Inc. (NASDAQ:PDEX)

OMERS ADMINISTRATION Corp acquired a new stake in shares of Pro-Dex, Inc. (NASDAQ:PDEX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 6,700 shares of the medical instruments supplier's stock, valued at approximately $313,000. OMERS ADMINISTRATION Corp owned approximately 0.21% of Pro-Dex at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the business. Northern Trust Corp boosted its position in shares of Pro-Dex by 14.1% during the 4th quarter. Northern Trust Corp now owns 35,754 shares of the medical instruments supplier's stock valued at $1,672,000 after purchasing an additional 4,426 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Pro-Dex by 2.2% in the third quarter. JPMorgan Chase & Co. now owns 24,790 shares of the medical instruments supplier's stock worth $740,000 after buying an additional 529 shares during the period. EAM Investors LLC acquired a new position in shares of Pro-Dex in the fourth quarter worth about $1,047,000. O Shaughnessy Asset Management LLC acquired a new position in shares of Pro-Dex in the fourth quarter worth about $995,000. Finally, 683 Capital Management LLC acquired a new position in shares of Pro-Dex in the fourth quarter worth about $739,000. Institutional investors own 15.28% of the company's stock.

Pro-Dex Stock Performance

Shares of PDEX opened at $43.23 on Tuesday. Pro-Dex, Inc. has a one year low of $16.84 and a one year high of $70.26. The company has a 50-day moving average of $53.29 and a two-hundred day moving average of $46.90. The stock has a market cap of $140.97 million, a price-to-earnings ratio of 21.51 and a beta of 0.37. The company has a debt-to-equity ratio of 0.33, a current ratio of 2.58 and a quick ratio of 1.44.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.98 EPS for the quarter, topping the consensus estimate of $0.47 by $0.51. Pro-Dex had a net margin of 11.06% and a return on equity of 21.68%. The company had revenue of $17.41 million during the quarter, compared to analysts' expectations of $17.70 million. On average, equities research analysts expect that Pro-Dex, Inc. will post 2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Pro-Dex from a "hold" rating to a "buy" rating in a report on Tuesday, May 13th.

Insider Buying and Selling

In related news, Director Raymond E. Cabillot sold 5,151 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $50.00, for a total transaction of $257,550.00. Following the completion of the sale, the director now directly owns 300,695 shares in the company, valued at approximately $15,034,750. This trade represents a 1.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Over the last three months, insiders sold 21,383 shares of company stock worth $1,031,182. 47.50% of the stock is owned by company insiders.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.